Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

By Latif Tahir   Wood Laura   Connell Cindy   Smith David C.   Vaughn David   Lebwohl David   Peereboom David  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 79-84

Springer Publishing Company

Access to resources Recommend Favorite

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

By Wierzbicki Rafal   Jonker Derek   Moore Malcolm   Berry Scott   Loehrer Patrick   Youssoufian Hagop   Rowinsky Eric  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 167-174

Springer Publishing Company

Access to resources Recommend Favorite

TNF-blockade in patients with advanced hormone refractory prostate cancer

By Diaz Luis   Messersmith Wells   Sokoll Lori   Sinibaldi Vicki   Moore Sandy   Carducci Michael   Eisenberger Mario  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 192-194

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

By Wu Jennifer   Henderson Charles   Feun Lynn   Veldhuizen Peter   Gold Philip   Zheng Hui   Ryan Theresa   Blaszkowsky Lawrence   Chen HaoBin   Costa Max   Rosenzweig Barry   Nierodzik MaryLynn   Hochster Howard   Muggia Franco   Abbadessa Giovanni   Lewis Jonathan   Zhu Andrew  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 670-676

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

By Goldstein D.   Ackland S.   Bell D.   Olver I.   Davis I.   Rosenthal M.   Toner G.   Pinel M.   Byrne M.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 429-434

Springer Publishing Company

Access to resources Recommend Favorite